PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Agilent CDx Assay IVDR Certified to ID Cancer Patients for Keytruda, Libtayo Treatment
The clearance applies to use of the companion diagnostic to identify patients with multiple cancer types for treatment with Merck's Keytruda and Regeneron's Libtayo.
Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering
The companies have been working together since 2021 following a strategic investment by Guardant in the South Korean AI firm.
Roche Gains IVDR Certificate for Cancer Treatment Companion Dx
TÜV SÜD, a European notified body, claimed it to be the first such certification of its kind.
Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq
The test gained European approval to identify PD-L1-expressing non-small cell lung cancer patients eligible for treatment with Roche's checkpoint inhibitor.
Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy
Premium
While the results are from a small study, investigators are working to validate them in larger groups, hoping their method can prove itself for clinical use.